CLI

DIDWW and INVADE collaborate to support predictive dialing for market research

Wednesday, September 22, 2021 - 2:21pm

INVADE's innovative dialer system will be supported by DIDWW, thereby enabling its customers to efficiently and cost-effectively conduct large-scale outbound phone surveys.

Key Points: 
  • INVADE's innovative dialer system will be supported by DIDWW, thereby enabling its customers to efficiently and cost-effectively conduct large-scale outbound phone surveys.
  • INVADE has extensive experience in working with market research software and, due to their product's modular design, they are able to create the best-in-class predictive dialer that meets unique business needs.
  • DIDWW and INVADE's partnership will ensure that global market research clients can benefit from secure, uninterrupted service, premium call quality and the ability to access local routes with guaranteed CLI.
  • DIDWW powerfulSIP trunking solution, delivered over a private, global IP network, offers virtually unlimited call capacity and flexible SIP trunk settings.

DIDWW and INVADE collaborate to support predictive dialing for market research

Wednesday, September 22, 2021 - 2:19pm

INVADE's innovative dialer system will be supported by DIDWW, thereby enabling its customers to efficiently and cost-effectively conduct large-scale outbound phone surveys.

Key Points: 
  • INVADE's innovative dialer system will be supported by DIDWW, thereby enabling its customers to efficiently and cost-effectively conduct large-scale outbound phone surveys.
  • INVADE has extensive experience in working with market research software and, due to their product's modular design, they are able to create the best-in-class predictive dialer that meets unique business needs.
  • DIDWW and INVADE's partnership will ensure that global market research clients can benefit from secure, uninterrupted service, premium call quality and the ability to access local routes with guaranteed CLI.
  • DIDWW powerfulSIP trunking solution, delivered over a private, global IP network, offers virtually unlimited call capacity and flexible SIP trunk settings.

Open Mainframe Project Announces Continued Growth in Community Contributions and Adoption as Mainframes Accelerate Innovation in Enterprise Hybrid Technology

Wednesday, September 22, 2021 - 1:00pm

The COBOL Working Group is currently working on the statistics but is giving a preview of the data at Open Mainframe Summit.

Key Points: 
  • The COBOL Working Group is currently working on the statistics but is giving a preview of the data at Open Mainframe Summit.
  • The project combines the processing power of GenevaERS, the reliability of the mainframe and the dynamics of an open-source community.
  • Getting this mainframe talent pool off to the best start is a commitment Open Mainframe Project is pursuing.
  • Together with the worldwide open source community, it is solving the hardest technology problems by creating the largest shared technology investment in history.

GitKraken Acquires BigBrassBand, Creator of Git Integration for Jira

Tuesday, September 21, 2021 - 5:30pm

GitKraken, the world's most popular Git client, has acquired BigBrassBand and its popular Git Integration for Jira.

Key Points: 
  • GitKraken, the world's most popular Git client, has acquired BigBrassBand and its popular Git Integration for Jira.
  • Git Integration for Jira combines Git data and workflows into a Jira team's project and issue-oriented context, while GitKraken presents Jira issues and projects to developers in a highly visual, intuitive, Git environment.
  • By leveraging GitKraken and Git Integration for Jira, teams using Git and Jira can now switch seamlessly between multiple developer workspaces while maintaining access to all the Git repo information and actions they need.
  • "The acquisition of Git Integration for Jira enables us to further enhance Git productivity for millions of companies that leverage both Git and Jira.

GitKraken Acquires BigBrassBand, Creator of Git Integration for Jira

Tuesday, September 21, 2021 - 5:30pm

Git Integration for Jira combines Git data and workflows into a Jira team's project and issue-oriented context, while GitKraken presents Jira issues and projects to developers in a highly visual, intuitive, Git environment.

Key Points: 
  • Git Integration for Jira combines Git data and workflows into a Jira team's project and issue-oriented context, while GitKraken presents Jira issues and projects to developers in a highly visual, intuitive, Git environment.
  • By leveraging GitKraken and Git Integration for Jira, teams using Git and Jira can now switch seamlessly between multiple developer workspaces while maintaining access to all the Git repo information and actions they need.
  • "The acquisition of Git Integration for Jira enables us to further enhance Git productivity for millions of companies that leverage both Git and Jira.
  • It launched the Git Integration for Jira app on the Atlassian Marketplace in 2012, which is now the highest-rated, top-selling, Git integration on the Atlassian Marketplace.

Liqid Brings Composable Disaggregated Infrastructure Software to the BIO-IT World (Booth #425) Expo & Conference in Boston

Monday, September 20, 2021 - 8:30pm

Were excited to share the benefits of Liqid Matrix CDI software with BIO-IT World attendees to help better facilitate breakthroughs driven by AI, including global R&D for pharmaceuticals and medical treatments.

Key Points: 
  • Were excited to share the benefits of Liqid Matrix CDI software with BIO-IT World attendees to help better facilitate breakthroughs driven by AI, including global R&D for pharmaceuticals and medical treatments.
  • Deploying Liqid Matrix CDI software, discovery and testing in the life sciences can be accelerated with adaptive, disaggregated IT infrastructure that can meet data demand is crucial for ongoing innovation.
  • Liqids composable infrastructure software platform, Liqid Matrix, unlocks cloud-like speed and flexibility plus higher efficiency from on-prem infrastructure.
  • Unlock cloud-like datacenter agility at any scale and experience new levels of resource and operational efficiency with Liqid.

Liqid Expands Leadership in Finance, Federal & Public Sector, and Product as the Company Continues to Grow Its Sales Footprint

Wednesday, September 15, 2021 - 4:30pm

Tucker joins Liqid as the company doubled its staff year-over-year and continues to expand its sales footprint across industry verticals in the public and private sectors.

Key Points: 
  • Tucker joins Liqid as the company doubled its staff year-over-year and continues to expand its sales footprint across industry verticals in the public and private sectors.
  • The company continues to grow its federal & public sector channel sales team with new appointments, as well as its product development leadership team to meet the unprecedented demand for industry-leading Liqid Matrix CDI software-based solutions.
  • Turman is responsible for a team of experienced sales leaders to offer Liqid Matrix software solutions to the marketplace.
  • He will be responsible for roadmap, product strategy, product management, and technical marketing for the Liqid Matrix platform.

Hemostemix Announces the First of a Series of 2021 Video Interviews with ACP-01 Recipients: What the Successful Compassionate Treatment of Ischemic Cardiomyopathy Looks Like After 13 Years

Tuesday, September 14, 2021 - 2:10pm

Hemostemix is a publicly traded autologous stem cell therapy company, founded in 2003.

Key Points: 
  • Hemostemix is a publicly traded autologous stem cell therapy company, founded in 2003.
  • A winner of the World Economic Forum Technology Pioneer Award, the Company developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia.
  • Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation.
  • This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable.

Applied BioMath, LLC to Present at Bio-IT World Conference & Expo

Tuesday, September 14, 2021 - 7:06pm

John Burke, PhD, Co-founder, President and CEO of Applied BioMath will present "Applied BioMath Assess - An Early Feasibility Assessment Tool for Biotherapeutics" within the Software Applications and Services track on Tuesday, September 21st at 10:30 a.m.

Key Points: 
  • John Burke, PhD, Co-founder, President and CEO of Applied BioMath will present "Applied BioMath Assess - An Early Feasibility Assessment Tool for Biotherapeutics" within the Software Applications and Services track on Tuesday, September 21st at 10:30 a.m.
  • In this presentation, Dr. Burke will demonstrate Applied BioMath Assess*, an interactive, web-based application that helps assess the difficulties and risks in developing a therapeutic very early-on.
  • Dr. Burke will explain how Applied BioMath Assess can help project teams answer questions such as:
    How does affinity impact target inhibition?
  • Applied BioMath and the Applied BioMath logo are registered trademarks of Applied BioMath, LLC.

In Honor of National Peripheral Artery Disease (PAD) Awareness Month, THE SAGE GROUP Comments on the Costs and Consequences of the Amputation Lottery

Tuesday, September 14, 2021 - 2:41pm

It is commonly believed that amputation costs the hospital less than revascularization procedures.

Key Points: 
  • It is commonly believed that amputation costs the hospital less than revascularization procedures.
  • Although initial procedure costs are similar, total amputation costs including the costs of in-hospital mortality, morbidity and revision procedures are higher than those of either bypass or endovascular.
  • Treatment with MA (above-the-knee amputation or below-the-knee amputation) rather than revascularization significantly increases the economic burden of critical limb ischemia (CLI).
  • THE SAGE GROUP, a research and consulting company, specializes in peripheral vascular disease, including venous disease, PAD and CLI, as well as the economic costs of these diseases.